Laden…
Synapedia is an independent knowledge project about psychoactive substances and harm reduction. If the platform helps you learn something new, you can support its development.
Every bit helps keep the project alive.
(6aR,9R)-N,N-diethyl-7-methyl-4-propanoyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide
1-Propionyl-LSD (1P-LSD) is a semi-synthetic lysergamide and structural analogue of LSD. The substance is enzymatically hydrolysed to LSD in the body and is therefore classified as a prodrug. Effects, dosage, and risk profile are largely identical to LSD. 1P-LSD has a half-life of approximately 10–12 hours and acts primarily as a partial agonist at the 5-HT2A receptor. Psychedelic effects include altered perception, visual hallucinations, and changes in cognition.
Receptor Targets
Mechanism of Action
Designations
IUPAC: 1P-LSD
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Substance Fingerprint
Pharmacological profile based on receptor binding, mechanism of action, and substance class. Limited data — interpret profile with caution.
Effects & Pharmacology is partially translated. Some content may appear in German.
1P-LSD (1-Propionyl-LSD) ist eine Prodrug für LSD. In vitro pharmakologisch nahezu inaktiv an 5-HT2A (Ki >1000 nM). In vivo spalten hepatische und intestinale Amidasen/Esterasen die 1-Propionyl-Gruppe, um LSD freizusetzen (Konversionshalbwertszeit ~1h). Die gesamte pharmakologische Aktivität stammt ausschließlich vom LSD-Metaboliten: 5-HT2A-Partialagonismus, 5-HT1A, 5-HT2C, D1/D2-Agonismus. Das Wirkprofil ist pharmakologisch identisch zu LSD, der Wirkungseintritt ist leicht verzögert durch die Prodrug-Konversion.
Known Effects
Individual effects may vary significantly. These are pharmacologically documented effects.
Total duration 8-12 hours
Peak
2-4 hours
Onset
30-60 minutes
Total duration
8-12 hours
After effects
2-6 hours
Start low. Individual sensitivity varies.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, and pre-existing conditions significantly affect outcomes.
Risks
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
MAO inhibitors
Serotonin reuptake inhibitors
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.